These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16481224)

  • 1. Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate.
    Pai MP; Allen SE; Amsden GW
    J Cyst Fibros; 2006 Aug; 5(3):153-7. PubMed ID: 16481224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: an open-label, randomized, two-period crossover comparison in healthy Mexican volunteers.
    Galan-Herrera JF; Poo JL; Rosales-Sanchez O; Fuentes-Fuentes E; Cariño L; Burke-Fraga V; Namur S; Parra MG
    Clin Ther; 2009 Aug; 31(8):1796-803. PubMed ID: 19808138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers.
    Wallace AW; Victory JM; Amsden GW
    J Clin Pharmacol; 2003 May; 43(5):539-44. PubMed ID: 12751275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two open-label, randomized, crossover studies assessing the bioequivalence of ofloxacin administered as immediate-and extended-release formulations in healthy subjects.
    Marier JF; Ducharme MP; DiMarco M; Di Spirito M; Morelli G; Tippabhotla SK; Badri N; Rampal A; Monif T
    Clin Ther; 2006 Dec; 28(12):2070-80. PubMed ID: 17296463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of levofloxacin after single intravenous and repeat oral administration to cats.
    Albarellos GA; Ambros LA; Landoni MF
    J Vet Pharmacol Ther; 2005 Aug; 28(4):363-9. PubMed ID: 16050816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.
    Conte JE; Golden JA; McIver M; Zurlinden E
    Int J Antimicrob Agents; 2006 Aug; 28(2):114-21. PubMed ID: 16837169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of P-glycoprotein inhibition on renal clearance of dicloxacillin in patients with cystic fibrosis.
    Beringer PM; Kriengkauykiat J; Zhang X; Hidayat L; Liu S; Louie S; Synold T; Burckart GJ; Rao PA; Shapiro B; Gill M
    Pharmacotherapy; 2008 Jul; 28(7):883-94. PubMed ID: 18576903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of intravenously administered levofloxacin in men and women.
    Overholser BR; Kays MB; Lagvankar S; Goldman M; Mueller BA; Sowinski KM
    Pharmacotherapy; 2005 Oct; 25(10):1310-8. PubMed ID: 16185174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of levofloxacin in healthy Thai male volunteers.
    Chulavatnatol S; Chindavijak B; Vibhagool A; Wananukul W; Sriapha C; Sirisangtragul C
    J Med Assoc Thai; 1999 Nov; 82(11):1127-35. PubMed ID: 10659548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics/pharmacodynamics of levofloxacin 750 mg once daily in young women with acute uncomplicated pyelonephritis.
    Nicolle L; Duckworth H; Sitar D; Bryski L; Harding G; Zhanel G
    Int J Antimicrob Agents; 2008 Mar; 31(3):287-9. PubMed ID: 18155885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levofloxacin pharmacokinetics in children.
    Chien S; Wells TG; Blumer JL; Kearns GL; Bradley JS; Bocchini JA; Natarajan J; Maldonado S; Noel GJ
    J Clin Pharmacol; 2005 Feb; 45(2):153-60. PubMed ID: 15647407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrapulmonary pharmacodynamics of high-dose levofloxacin in subjects with chronic bronchitis or chronic obstructive pulmonary disease.
    Conte JE; Golden JA; McIver M; Little E; Zurlinden E
    Int J Antimicrob Agents; 2007 Nov; 30(5):422-7. PubMed ID: 17716873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.
    Kiser TH; Hoody DW; Obritsch MD; Wegzyn CO; Bauling PC; Fish DN
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1937-45. PubMed ID: 16723549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
    Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
    Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in healthy volunteers.
    Hart D; Weinstein MP
    Diagn Microbiol Infect Dis; 2007 Jul; 58(3):375-8. PubMed ID: 17449210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levofloxacin pharmacokinetics in adult cystic fibrosis.
    Lee CKK; Boyle MP; Diener-West M; Brass-Ernst L; Noschese M; Zeitlin PL
    Chest; 2007 Mar; 131(3):796-802. PubMed ID: 17356095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and effects on bowel and throat microflora of oral levofloxacin as antibacterial prophylaxis in neutropenic patients with haematological malignancies.
    Timmers GJ; Dijstelbloem Y; Simoons-Smit AM; van Winkelhoff AJ; Touw DJ; Vandenbroucke-Grauls CM; Huijgens PC
    Bone Marrow Transplant; 2004 Apr; 33(8):847-53. PubMed ID: 14755314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.